Differential phosphofructokinase‑1 isoenzyme patterns associated with glycolytic efficiency in human breast cancer and paracancer tissues

Wang,Guannan; Xu,Zhiliang; Wang,Changhua; Yao,Feng; Li,Juanjuan; Chen,Chuang; Sun,Shengrong

doi:10.3892/ol.2013.1599

Differential phosphofructokinase‑1 isoenzyme patterns associated with glycolytic efficiency in human breast cancer and paracancer tissues

Authors:
- Guannan Wang
- Zhiliang Xu
- Changhua Wang
- Feng Yao
- Juanjuan Li
- Chuang Chen
- Shengrong Sun
View Affiliations

Affiliations: Department of Breast and Thyroid Surgery, Renmin Hospital, Wuhan University, Wuhan, Hubei, P.R. China, Department of Pathology and Physiology, The Medical College, Wuhan University, Wuhan, Hubei, P.R. China
Published online on: October 1, 2013 https://doi.org/10.3892/ol.2013.1599
Pages: 1701-1706

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancers are characterized by an increasing glycolytic activity, which is called the Warburg effect. Although this phenomenon is well known, the mechanism of the enhanced rate of glycolysis in cancer has not yet been clearly recognized. The present study investigated the glycolytic rate, regulatory enzymatic activities and the expression of phosphofructokinase‑1 (PFK‑1) in human breast cancer and paracancer tissues. Human breast cancer tissues have an increased degree of glycolytic efficiency and regulatory enzymatic activities, which have been shown in previous studies. However, the present study identified a number of novel observations. The total PFK‑1 levels were higher in human breast cancer tissues than in paracancer tissues, and further investigations revealed differential PFK‑1 isoenzyme expression patterns between human breast cancer and paracancer tissues. The human breast cancer and paracancer tissues mainly expressed PFK‑P and PFK‑L isoforms, respectively. Linear‑regression analysis showed that, depending on the pathological stage of breast cancer, the expression of PFK‑P was significantly positively correlated with the activity of PFK‑1. Thus, during the development of human breast cancer, the enhancement of glycolytic activity depends primarily on the conversion of the PFK‑1, from PFK‑L to PFK‑P.

View Figures

View References

1	Szutowicz A, Kwiatkowski J and Angielski S: Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast. Br J Cancer. 39:681–687. 1979. View Article : Google Scholar : PubMed/NCBI
2	Hennipman A, Smits J, van Oirschot B, van Houwelingen JC, Rijksen G, Neyt JP, Van Unnik JA and Staal GE: Glycolytic enzymes in breast cancer, benign breast disease and normal breast tissue. Tumour Biol. 8:251–263. 1987. View Article : Google Scholar : PubMed/NCBI
3	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
4	Drake B and Cook GJ: Positron emission tomography computed tomography in oncology. Br J Hosp Med (Lond). 72:631–637. 2011. View Article : Google Scholar : PubMed/NCBI
5	Robey IF, Stephen RM, Brown KS, Baggett BK, Gatenby RA and Gillies RJ: Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia. 10:745–756. 2008.PubMed/NCBI
6	Gottlieb E and Tomlinson IP: Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer. 5:857–866. 2005. View Article : Google Scholar : PubMed/NCBI
7	Guppy M, Leedman P, Zu X and Russell V: Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem J. 364:309–315. 2002.PubMed/NCBI
8	Dalgard CL, Lu H, Mohyeldin A and Verma A: Endogenous 2-oxoacids differentially regulate expression of oxygen sensors. Biochem J. 380:419–424. 2004. View Article : Google Scholar : PubMed/NCBI
9	Papandreou I, Cairns RA, Fontana L, Lim AL and Denko NC: HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3:187–197. 2006. View Article : Google Scholar : PubMed/NCBI
10	Macheda ML, Rogers S and Best JD: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 202:654–662. 2005. View Article : Google Scholar : PubMed/NCBI
11	El-Bacha T, de Freitas MS and Sola-Penna M: Cellular distribution of phosphofructokinase activity and implications to metabolic regulation in human breast cancer. Mol Genet Metab. 79:294–299. 2003. View Article : Google Scholar : PubMed/NCBI
12	Vora S, Halper JP and Knowles DM: Alterations in the activity and isozymic profile of human phosphofructokinase during malignant transformation in vivo and in vitro: transformation- and progression-linked discriminants of malignancy. Cancer Res. 45:2993–3001. 1985.
13	Dunaway GA: A review of animal phosphofructokinase isozymes with an emphasis on their physiological role. Mol Cell Biochem. 52:75–91. 1983. View Article : Google Scholar : PubMed/NCBI
14	Zancan P, Sola-Penna M, Furtado CM and Da Silva D: Differential expression of phosphofructokinase-1 isoforms correlates with the glycolytic efficiency of breast cancer cells. Mol Genet Metab. 100:372–378. 2010. View Article : Google Scholar : PubMed/NCBI
15	Šmerc A, Sodja E and Legiša M: Posttranslational modification of 6-phosphofructo-1-kinase as an important feature of cancer metabolism. PLoS One. 6:e196452011.PubMed/NCBI
16	Shonk CE and Boxer GE: Enzyme patterns in human tissues. I. Methods for the determination of glycolytic enzymes. Cancer Res. 24:709–721. 1964.PubMed/NCBI
17	Coelho WS, Costa KC and Sola-Penna M: Serotonin stimulates mouse skeletal muscle 6-phosphofructo-1-kinase through tyrosine-phosphorylation of the enzyme altering its intracellular localization. Mol Genet Metab. 92:364–370. 2007. View Article : Google Scholar
18	Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004. View Article : Google Scholar : PubMed/NCBI
19	Hennipman A, van Oirschot BA, Smits J, Rijksen G and Staal GE: Glycolytic enzyme activities in breast cancer metastases. Tumour Biol. 9:241–248. 1988. View Article : Google Scholar
20	Hennipman A, van Oirschot BA, Smits J, Rijksen G and Staal GE: Heterogeneity of glycolytic enzyme activity and isozyme composition of pyruvate kinase in breast cancer. Tumour Biol. 9:178–189. 1988. View Article : Google Scholar : PubMed/NCBI
21	Hron WT and Menahan LA: Age-related changes in activities of hepatic phosphofructokinase, pyruvate kinase and pyruvate dehydrogenase in liver and adipose tissue of the swiss albino mouse. Enzyme. 30:83–88. 1983.
22	Steffen V, Gordillo E, Castano A, Caño J and Machado A: Age-dependent changes in the activity and isoenzymatic pattern of the phosphofructokinase in different areas of the central nervous systems. Neurosci Lett. 125:15–18. 1991. View Article : Google Scholar : PubMed/NCBI
23	Jia SS and Liu YH: Effects of estrogen on the expression of phosphofructokinase muscle-specific isoform in genioglossus of chronic intermittent hypoxia rats. Zhonghua Kou Qiang Yi Xue Za Zhi. 45:627–630. 2010.(In Chinese).
24	Augoff K and Grabowski K: Significance of lactate dehydrogenase measurements in diagnosis of malignancies. Pol Merkur Lekarski. 17:644–647. 2004.(In Polish).
25	Sánchez-Martínez C and Aragon JJ: Analysis of phosphofructokinase subunits and isozymes in ascites tumor cells and its original tissue, murine mammary gland. FEBS Lett. 409:86–90. 1997.PubMed/NCBI
26	Moon JS, Kim HE, Koh E, Park SH, Jin WJ, Park BW, Park SW and Kim KS: Krüppel-like factor 4 (KLF4) activates the transcription of the gene for the platelet isoform of phosphofructokinase (PFKP) in breast cancer. J Biol Chem. 286:23808–23816. 2011.